NEJM- Nov 2015 – ANNEXA-A and ANNEXA-R ClinicalTrials
As of now the major limiting factor with the use of novel anticoagulants is the absence of reversal agents in case of bleeding complications.
To find a solution to this problem, a new drug has been recently tested in ANNEXA-A and ANNEXA-R trials. Andexanet alfa, a new drug designed to reverse factor X a inhibition.
In the trial, Andexanet alfa was given to apixaban and rivoraxaban administrated healthy volunteers. Within minutes of administration anti factor Xa activity was reduced by more than 90% without any toxic or serious thrombotic effects.